

N = 6560

**UA/NSTEMI**

Follow-up  
Q4 mo  
(Avg 8-12 mo)

**Ranolazine  
IV to PO**

**RANDOMIZE (1:1)  
Double-blind**

**Placebo  
Matched IV/PO**

**Holter at enrollment x 7d**

**Follow-up Visits:  
Day 14, Month 4,  
Q4 Months**

**ETT Month 8**

**Final Visit**

**Primary Endpoint: CV death, MI or Recurrent Ischemia**




Primary Endpoint - CV Death, MI, or Recurrent Ischemia


21.8% for Ranolazine vs. 23.5% for Placebo

HR 0.92 (95% CI 0.83 to 1.02), P = 0.11

## CV Death or MI (%)




## Recurrent Ischemia (%)



\*KM Cumulative Incidence (%) at 12 months

## Ventricular Arrhythmias

■ Ranolazine    ■ Placebo



## Effect of Ranolazine on HbA1c in Patients with DM

